← Leaderboards
David E. Pleasure
University Of California At Davis
$7,401,421
Attributed
$7,613,390
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $713.8K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$9,835,117 · 10
By mechanism
R01$3,854,748 · 1
P50$2,221,727 · 1
R21$1,718,439 · 4
T32$1,066,622 · 1
P30$520,169 · 1
P01$320,794 · 1
Top collaborators
- Aijun Wang1 shared
Most similar at University Of California At Davis
Same institution · by research overlap
- Aijun Wang$6,380,053
Others in their field
Top investigators on “Oligodendroglia”
- Brian J Popko · Northwestern University$17,744,920
- Patrizia Casaccia · Univ Of Med/Dent Nj-R W Johnson Med Sch$16,342,723
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,144,108
- Stephen Arthur Back · Oregon Health & Science University$14,340,802
- Li-Huei Tsai · Massachusetts Institute Of Technology$14,042,281
- Vittorio Gallo · Child Health And Human Development$13,953,550
Research focus
OligodendrogliaGlutamate ReceptorPreventMediatingNeuropathologyReportingMonoclonal AntibodyNeuronsVoltage /Patch ClampImmunocytochemistryBrainAffectMyelinMitochondriaLaboratory MouseApoptosisSpinal CordMyelinationCell DeathMultiple SclerosisNeurogeneticsAxonLesionNeurologic
Grant awards (36)
Nanoparticle-mediated delivery of a base editor for in utero treatment of Canavan Disease$423,939
R21 · FY2023 · NS
Manipulating N-acetyl-L-aspartate transport to treat Canavan leukodystrophy$196,250
R21 · FY2023 · NS · contact PI
Manipulating N-acetyl-L-aspartate transport to treat Canavan leukodystrophy$235,500
R21 · FY2022 · NS · contact PI
Manipulating N-acetyl-L-aspartate to reverse Canavan leukodystrophy$431,750
R21 · FY2020 · NS · contact PI
CANAVAN DISEASE: SUPPRESSING THE PHENOTYPE BY INHIBITING NAA SYNTHESIS$196,250
R21 · FY2016 · NS · contact PI
CANAVAN DISEASE: SUPPRESSING THE PHENOTYPE BY INHIBITING NAA SYNTHESIS$234,750
R21 · FY2015 · NS · contact PI
Excitotoxicity in EAE$270,113
R01 · FY2011 · NS · contact PI
Excitotoxicity in EAE$272,869
R01 · FY2010 · NS · contact PI
Excitotoxicity in EAE$275,625
R01 · FY2009 · NS · contact PI
CORE--CELLULAR NEUROSCIENCE CORE$264,895
P30 · FY2009 · HD · contact PI
Excitotoxicity in EAE$173,250
R01 · FY2009 · NS · contact PI
Excitotoxicity in EAE$275,625
R01 · FY2008 · NS · contact PI
CORE--CELLULAR NEUROSCIENCE CORE$255,274
P30 · FY2008 · HD · contact PI
EXCITOTOXICITY IN EAE$298,970
R01 · FY2007 · NS · contact PI
EXCITOTOXICITY IN EAE$307,900
R01 · FY2006 · NS · contact PI
EXCITOTOXICITY IN EAE$352,468
R01 · FY2005 · NS
EXCITOTOXICITY IN EAE$345,488
R01 · FY2004 · NS
TRAINING GRANT IN NEUROLOGICAL DISORDERS AND STROKE$217,026
T32 · FY2004 · NS
DEATH OF IMMATURE OLIGODENDROGLIA$309,528
R01 · FY2003 · NS
TRAINING GRANT IN NEUROLOGICAL DISORDERS AND STROKE$219,100
T32 · FY2003 · NS
TRAINING GRANT IN NEUROLOGICAL DISORDERS AND STROKE$44,285
T32 · FY2003 · NS
DEATH OF IMMATURE OLIGODENDROGLIA$303,037
R01 · FY2002 · NS
TRAINING GRANT IN NEURODEVELOPMENTAL DISABILITIES$207,868
T32 · FY2002 · NS
CORE--CELLULAR NEUROSCIENCE CORE$0
P30 · FY2002 · HD
HUMAN NEUROMUSCULAR DISEASES$1,126,541
P50 · FY2001 · NS
DEATH OF IMMATURE OLIGODENDROGLIA$296,734
R01 · FY2001 · NS
TRAINING GRANT IN NEURODEVELOPMENTAL DISABILITIES$184,523
T32 · FY2001 · NS
CORE--CELLULAR NEUROSCIENCE CORE$0
P30 · FY2001 · HD
HUMAN NEUROMUSCULAR DISEASES$1,095,186
P50 · FY2000 · NS
CORE--CELL CULTURE AND BIOCHEMISTRY$320,794
P01 · FY2000 · NS
DEATH OF IMMATURE OLIGODENDROGLIA$288,141
R01 · FY2000 · NS
TRAINING GRANT IN NEURODEVELOPMENTAL DISABILITIES$193,820
T32 · FY2000 · NS
IMPROVING THE ANIMAL FACILITY$132,618
G20 · FY2000 · RR
DEATH OF IMMATURE OLIGODENDROGLIA$50,000
R01 · FY2000 · NS
DEATH OF IMMATURE OLIGODENDROGLIA$35,000
R01 · FY2000 · NS
CORE--CELLULAR NEUROSCIENCE CORE$0
P30 · FY2000 · HD